CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 4.630
+0.070 (1.54%)
Jun 18, 2026, 4:08 PM HKT
CStone Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -437 | -91.21 | -367.23 | -902.68 | -1,920 |
Depreciation & Amortization | 43.91 | 49.74 | 56.93 | 42.03 | 20.06 |
Other Amortization | 0.07 | 0.07 | 1.27 | 2.51 | 2.6 |
Loss (Gain) From Sale of Assets | - | -0.38 | -178.89 | - | 0.9 |
Asset Writedown & Restructuring Costs | 16.8 | 10.73 | 26.4 | 23.41 | - |
Loss (Gain) From Sale of Investments | 2.63 | -6.01 | -0.06 | 62.03 | 64.21 |
Stock-Based Compensation | 23.97 | -2.81 | 36.99 | 142.06 | 222.67 |
Other Operating Activities | 94.81 | -2.31 | -26.8 | -54.48 | 85.93 |
Change in Accounts Receivable | 50.12 | 88.48 | -95.31 | 40.47 | -117.6 |
Change in Inventory | 81.99 | -174.9 | -95.46 | 30.42 | -86.18 |
Change in Accounts Payable | -202.98 | -170.1 | -121.6 | -3.1 | 153.08 |
Change in Unearned Revenue | - | 35 | 70 | - | -6.76 |
Change in Other Net Operating Assets | -2.05 | -39.51 | 104.92 | 6.59 | 97.17 |
Operating Cash Flow | -327.75 | -303.21 | -588.84 | -610.74 | -1,484 |
Capital Expenditures | - | - | -0.02 | - | -91.03 |
Sale of Property, Plant & Equipment | - | 0.41 | 0.11 | - | - |
Sale (Purchase) of Intangibles | - | - | 151.57 | -101.82 | -58.11 |
Investment in Securities | 123.46 | -254.13 | 447.69 | 463.81 | -687.48 |
Other Investing Activities | 10.53 | 6.05 | 20.25 | 1.41 | 10.06 |
Investing Cash Flow | 133.99 | -247.68 | 619.61 | 363.39 | -826.55 |
Long-Term Debt Issued | 265 | 278 | 350 | 113.04 | 96.22 |
Long-Term Debt Repaid | -273.14 | -312.02 | -289.98 | -75.3 | -18.5 |
Net Debt Issued (Repaid) | -8.14 | -34.02 | 60.02 | 37.75 | 77.72 |
Issuance of Common Stock | 672.46 | 0.07 | 341.82 | 2.53 | 16.83 |
Other Financing Activities | -86.54 | -18.92 | -13.49 | -11.81 | -2.24 |
Financing Cash Flow | 577.78 | -52.86 | 388.36 | 28.47 | 92.3 |
Foreign Exchange Rate Adjustments | -18.26 | -4.98 | 18.87 | 34.84 | -63.55 |
Net Cash Flow | 365.76 | -608.73 | 437.99 | -184.04 | -2,282 |
Free Cash Flow | -327.75 | -303.21 | -588.86 | -610.74 | -1,575 |
Free Cash Flow Margin | -121.58% | -74.46% | -126.95% | -126.88% | -646.26% |
Free Cash Flow Per Share | -0.24 | -0.24 | -0.47 | -0.52 | -1.35 |
Cash Interest Paid | 10.88 | 11.9 | 10.18 | 11.81 | 2.24 |
Cash Income Tax Paid | 13.06 | - | - | - | - |
Levered Free Cash Flow | -251.06 | -233.08 | -495.11 | -398.41 | -1,054 |
Unlevered Free Cash Flow | -242.77 | -223.6 | -487.73 | -393.11 | -1,052 |
Change in Working Capital | -72.93 | -261.03 | -137.45 | 74.37 | 39.7 |